Opens in a new tab
Monday, 16 November 2026
EVIDENCE. INTERPRETED.
Pharmacally

NSCLC

Approvals, trial readouts, research and drug safety alerts, interpreted by pharmacists and checked against the primary source.

Advertisement · Remove ads
970 × 90

Latest in NSCLC

16 stories · every one Fact-Checked
OncoC4's investigational PD-1/VEGF bispecific antibody cesalatamig showing antitumor activity in previously treated non-small cell lung cancer.Health TidingsOncoC4 Reports 33% Response Rate with Cesalatamig in NSCLCOncoC4 reported a 33% objective response rate and 90% disease control rate with its investigational PD-1/VEGF bispecific antibody cesalatamig at 10 mg/kg in previously treated PD-(L)1-resistant or refractory…6 Nov 2026 · 4 min read
Fact-Checked
Akeso's ivonescimab plus chemotherapy achieves 70.1% major pathological response in resectable non-small cell lung cancer.Clinical TrialsAkeso Reports Strong Pathological Responses With Ivonescimab in NSCLCAkeso’s Phase II study published in Nature Medicine reports a 70.1% major pathological response and 50.7% pathological complete response with perioperative ivonescimab plus chemotherapy in resectable NSCLC.6 Nov 2026 · 5 min read
Fact-Checked
Illustration of dual EGFR and MET inhibition with osimertinib and savolitinib in EGFR-mutated, MET-overexpressing non-small cell lung cancerClinical TrialsHUTCHMED Reports 24.9-Month PFS With First-Line Savolitinib CombinationHUTCHMED’s Phase III SANOVO trial found that savolitinib plus osimertinib extended median progression-free survival by 11.1 months versus osimertinib alone in previously untreated EGFR-mutated, MET-overexpressing advanced NSCLC.29 Oct 2026 · 4 min read
Fact-Checked
Illustration of a bispecific antibody-drug conjugate targeting EGFR and HER3 in EGFR-mutated non-small cell lung cancerHealth TidingsSystImmune Reports Higher Response Rates With Izalontamab Brengitecan in NSCLCIzalontamab brengitecan nearly doubled median progression-free survival in the Phase 3 PANKU-Lung01 trial, reaching 11.1 months versus 5.7 months with platinum-based chemotherapy in previously treated EGFR-mutated non-small cell…26 Oct 2026 · 4 min read
Fact-Checked
Scientific illustration of EGFR-mutant non-small cell lung cancer and brain metastases, representing enozertinib's systemic and intracranial activityClinical TrialsORIC Plans Phase 3 After Positive Enozertinib Results in NSCLCORIC Pharmaceuticals reported an 84% investigator-assessed response rate and a 70% intracranial response rate with enozertinib in first-line EGFR atypical NSCLC.23 Oct 2026 · 4 min read
Fact-Checked
BH-30643 shows clinical activity in EGFR C797S-positive non-small cell lung cancerHealth TidingsBH-30643 Shows 45% Response Rate in EGFR C797S NSCLCBlossomHill Therapeutics’ investigational BH-30643 demonstrated a 45% objective response rate and 88% disease control rate in patients with EGFR C797S-positive NSCLC who had developed resistance to prior EGFR…15 Sep 2026 · 3 min read
Fact-Checked
BH-30643 receives FDA Fast Track designation for EGFR C797S-positive non-small cell lung cancerHealth TidingsBlossomHill’s BH-30643 Gets FDA Fast Track Designation for EGFR C797S-Positive NSCLCBlossomHill Therapeutics’ investigational EGFR inhibitor BH-30643 has received FDA Fast Track designation for adults with advanced or metastatic EGFR C797S-positive non-small cell lung cancer after prior treatment with…18 Aug 2026 · 3 min read
Fact-Checked
Tinlarebant receives FDA Priority Review for Stargardt Disease Type 1Clinical TrialsAmplia and Lilly Partner to Advance Narmafotinib Plus Olomorasib for KRAS G12C-Mutant NSCLCAmplia Therapeutics has entered a clinical trial collaboration with Eli Lilly to evaluate the combination of the investigational FAK inhibitor narmafotinib and the KRAS G12C inhibitor olomorasib in…4 Aug 2026 · 3 min read
Fact-Checked
Phase 1 clinical trial illustration showing ENV-105 (carotuximab) combined with osimertinib demonstrating a favorable safety profile in EGFR-mutated non-small cell lung cancer.Clinical TrialsKairos Reports Favorable Safety Data for ENV-105 Plus Osimertinib in EGFR-Mutated NSCLCKairos Pharma has reported encouraging interim Phase 1 safety data for ENV-105 (carotuximab) combined with osimertinib in advanced EGFR-mutated non-small cell lung cancer.16 Jul 2026 · 3 min read
Fact-Checked
Illustration of sacituzumab tirumotecan (sac-TMT) combined with pembrolizumab improving progression-free survival in patients with PD-L1-negative advanced non-squamous non-small cell lung cancer in the Phase III OptiTROP-Lung06 trial.Clinical TrialsKelun-Biotech Reports Positive Phase III OptiTROP-Lung06 Results in NSCLCKelun-Biotech reported positive Phase III OptiTROP-Lung06 results, with sacituzumab tirumotecan plus pembrolizumab significantly improving progression-free survival versus standard pembrolizumab and chemotherapy in first-line PD-L1-negative non-squamous NSCLC, supporting a…15 Jul 2026 · 3 min read
Fact-Checked
Illustration of eftilagimod alfa (efti) immunotherapy showing mature Phase I INSIGHT-003 overall survival results in first-line non-squamous NSCLC alongside the ongoing TACTI-004 root cause investigation.Clinical TrialsImmutep Reports 30.9-Month Overall Survival in Phase I INSIGHT-003 Trial of Efti for First-Line NSCLCImmutep reported mature Phase I INSIGHT-003 data showing a median overall survival of 30.9 months with eftilagimod alfa (efti) plus pembrolizumab and chemotherapy in first-line non-squamous NSCLC.14 Jul 2026 · 3 min read
Fact-Checked
Evexta Bio and Roche collaboration for rupitasertib and giredestrant combination in ESR1-mutated breast cancer trialClinical TrialsMAIA Reports 90.5% Disease Control Rate with Ateganosine Plus Cemiplimab in NSCLC TrialMAIA Biotechnology has announced encouraging interim results from Part C of its Phase 2 THIO‑101 trial (NCT05208944), where the telomere‑targeting agent ateganosine achieved a 90.5% disease control rate…8 Jul 2026 · 4 min read
Fact-Checked
Page 1 of 2